Your Health, We Care
Another NameOrserdu、依拉司群、RAD1901、埃拉司群、艾拉司群
IndicationsIndicated for ER-positive, HER2-negative, ESR1-mutant advanced/metastatic breast cancer in postmenopausal women or adult men with disease progression after at least one line of endocrine therapy.
Reg No.09 L 1197/24
Inspection NO.2127-24
Elacestrant is a prescription drug targeting estrogen receptor alpha (ERα), approved by the U.S. FDA in January 2023, and should be used strictly in accordance with medical advice.
Estrogen Receptor alpha (ERα)
Elacestrant binds to and degrades estrogen receptor alpha (ERα). At concentrations that induce ERα degradation in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer cells, it inhibits 17β-estradiol-mediated cell proliferation.
Route and Frequency of Administration for Elacestrant: Oral administration, 345 mg once daily.
The dosage of Elacestrant needs to be adjusted according to the patient's actual condition. For specific circumstances, patients should consult a doctor and follow medical advice strictly.
Recommended Reading: Dosage and Administration of Elacestrant
Common Adverse Reactions: Musculoskeletal pain, nausea, elevated blood cholesterol and triglyceride levels, etc.
Serious Adverse Reactions: Elevated blood lipid levels (hypercholesterolemia and hypertriglyceridemia).
Reference Article: Adverse Reactions of Elacestrant
Pregnancy: Contraindicated in patients who are pregnant or planning to become pregnant. Elacestrant may cause harm to the unborn baby.
Lactation: It is unknown whether Elacestrant is excreted in human breast milk. Breastfeeding is not recommended during treatment with Elacestrant and for 1 week after the last dose.
1. Inform patients that hypercholesterolemia and hypertriglyceridemia may occur with Elacestrant use. Remind patients that clinicians will assess lipid profiles prior to the initiation of Elacestrant therapy and conduct regular monitoring during treatment.
2. Instruct patients to take Elacestrant at approximately the same time each day with food to reduce the risk of nausea and vomiting. Advise patients to swallow Elacestrant tablets whole; do not crush, chew, or split the tablets before swallowing.
3. Inform patients that if a dose of Elacestrant is missed by more than 6 hours, or if vomiting occurs after taking a dose, skip the missed dose and take the next scheduled dose on the following day at the regular time.
from FDA，2023.05
